DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Gene Therapy Market (3rd Edition), 2019-2030 report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, and genome editing therapies. The study also features an elaborate discussion on the future potential of this evolving market.

Since the approval of the first therapy, Genedicine in 2003, the gene therapy domain has evolved significantly. Specifically, in 2019, three gene therapies, namely Zolgensma (US), Zynteglo (Europe) and Beperminogene Perplasmid (Japan), have received approval / conditional approval, leading to a marked upward surge in the interest in this field.

In fact, the growing popularity can be correlated to the substantial increase (more than 90%) in the number of patents that have been filed/granted in the last three years. Moreover, in the same time period, more than USD 12.5 billion in the capital has been invested by various private and public investors to fund research activities. Presently, there are more than 10 approved gene therapies in the market, while many others are being investigated across various phases of clinical research.

Over time, the efforts of industry stakeholders and clinical researchers have led to the discovery of novel molecular targets, thereby, strengthening the research pipelines of companies involved in the development of gene therapies. Further, several technology developers have designed innovative ways to improve the efficacy and safety of gene therapies and introduced advanced therapy development and vector engineering platforms.

It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the M&A activity in this domain, including the involvement of several big pharma players as well. The capability of such therapies to target diverse disease indications is considered to be amongst the most prominent growth drivers of this market. Backed by promising clinical results and several therapy candidates in late phases of development, we believe that the overall market is expected to witness tremendous growth in the coming decade.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for gene therapies, for the next decade. Based on multiple parameters, such as target patient population, likely adoption rates, and expected pricing, we have provided informed estimates on the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across:

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Amongst other elements, the report features:

Key Topics Covered:

1 Preface

2 Executive Summary

3 Introduction

4 Gene Delivery Vectors

5 Regulatory Landscape And Reimbursement Scenario

6 Competitive Landscape

7 Marketed Gene Therapies

8 Key Commercialization Strategies

9 Late Stage (Phase Ii/Iii And Above) Gene Therapies

10 Emerging Technologies

11 Promising Therapeutics Areas

12 Patent Analysis

13 Mergers And Acquisitions

14 Funding And Investment Analysis

15 Cost Price Analysis

16 Big Pharma Players: Analysis Of Gene Therapy Related Initiatives

17 Market Forecast And Opportunity Analysis

18 Vector Manufacturing

19 Case Study: Gene Therapy Supply Chain

20 Conclusion

21 Interview Transcripts

22 Appendix 1: Tabulated Data

23 Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/r/pbrmpf

Read the original:
Global Gene Therapy Market, 2019-2030: Current Market Landscape of Gene Augmentation-Based Therapies, Oncolytic Viral Therapies, and Genome Editing...

Comments are closed.